Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 452-459

  Krug, P W ^a,c   Schinazi, R F ^b   Hilliard, J K ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; THYMIDINE KINASE; VIDARABINE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HERPES SIMPLEX VIRUS 1; MACACA; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

ACYCLOVIR; AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DNA, VIRAL; GANCICLOVIR; GENOTYPE; HERPESVIRUS 1, CERCOPITHECINE; MOLECULAR SEQUENCE DATA; PLAQUE ASSAY; PLASMIDS; THYMIDINE KINASE; VERO CELLS; VIDARABINE;

EID: 73849130548     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01435-08     Document Type: Article

References (39)

1. Abbruzzese, J. L., S. Schmidt, M. N. Raber, J. K. Levy, A. M. Castellanos, S. S. Legha, and I. H. Krakoff. 1989. Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl) -5-methyluracil (FMAU) terminated by severe neurologic toxicity. Invest. New Drugs 7:195-201.
2. Anderson, D. C., R. B. Swenson, J. L. Orkin, S. S. Kalter, and H. M. McClure. 1994. Primary Herpesvirus simiae (B-virus) infection in infant macaques. Lab. Anim. Sci. 44:526-530.
3. Artenstein, A. W., C. B. Hicks, B. S. Goodwin, Jr., and J. K. Hilliard. 1991. Human infection with B virus following a needlestick injury. Rev. Infect. Dis. 13:288-291.
4. Balzarini, J., and E. De Clercq. 1990. 9-Beta-D- arabinofuranosyladenine 5′-monophosphate (araAMP) is converted directly to its antivirally active 5′-triphosphate form by 5-phosphoribosyl-1- pyrophosphate (PRPP) synthetase. Biochem. Biophys. Res. Commun. 173:781-787.
5. Boulter, E. A., and D. P. Grant. 1977. Latent infection of monkeys with B virus and prophylactic studies in a rabbit model of this disease. J. Antimicrob. Chemother. 3(Suppl. A):107-113.
6. Boulter, E. A., B. Thornton, D. J. Bauer, and A. Bye. 1980. Successful treatment of experimental B virus (Herpesvirus simiae) infection with acyclovir. Br. Med. J. 280:681-683.
7. Centers for Disease Control. 1989. B virus infections in humans - Michigan. MMWR Morb. Mortal. Wkly. Rep. 38:453-454.
8. Centers for Disease Control. 1987. B-virus infection in humans - Pensacola, Florida. MMWR Morb. Mortal. Wkly. Rep. 36:289-290, 295-296.
9. Centers for Disease Control and Prevention. 1998. Fatal Cercopithecine herpesvirus 1 (B virus) infection following a mucocutaneous exposure and interim recommendations for worker protection. MMWR Morb. Mortal. Wkly. Rep. 47:1073-1076, 1083.
10. Centers for Disease Control and Prevention. 1995. Publication of guidelines for the prevention and treatment of B virus infections in exposed persons. MMWR Morb. Mortal. Wkly. Rep. 44:96-97.
11. Chou, T. C., X. B. Kong, M. P. Fanucchi, Y. C. Cheng, K. Takahashi, K. A. Watanabe, and J. J. Fox. 1987. Synthesis and biological effects of 2′-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil. Antimicrob. Agents Chemother. 31: 1355-1358.
12. Davenport, D. S., D. R. Johnson, G. P. Holmes, D. A. Jewett, S. C. Ross, and J. K. Hilliard. 1994. Diagnosis and management of human B virus (Herpesvirus simiae) infections in Michigan. Clin. Infect. Dis. 19:33-41.
13. Fanucchi, M. P., B. Leyland-Jones, C. W. Young, J. H. Burchenal, K. A. Watanabe, and J. J. Fox. 1985. Phase I trial of 1-(2′-deoxy-2′- fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU). Cancer Treat. Rep. 69:55-59.
14. Focher, F., A. Lossani, A. Verri, S. Spadari, A. Maioli, J. J. Gambino, G. E. Wright, R. Eberle, D. H. Black, P. Medveczky, M. Medveczky, and D. Shugar. 2007. Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob. Agents Chemother. 51:2028-2034.
15. Holmes, G. P., L. E. Chapman, J. A. Stewart, S. E. Straus, J. K. Hilliard, and D. S. Davenport. 1995. Guidelines for the prevention and treatment of B-virus infections in exposed persons. The B Virus Working Group. Clin. Infect. Dis. 20:421-439.
16. Holmes, G. P., J. K. Hilliard, K. C. Klontz, A. H. Rupert, C. M. Schindler, E. Parrish, D. G. Griffin, G. S. Ward, N. D. Bernstein, T. W. Bean, et al. 1990. B virus (Herpesvirus simiae) infection in humans: epidemiologic investigation of a cluster. Ann. Intern. Med. 112:833-839.
17. Kong, X. B., A. C. Scheck, R. W. Price, P. M. Vidal, M. P. Fanucchi, K. A. Watanabe, J. J. Fox, and T. C. Chou. 1988. Incorporation and metabolism of 2′-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells. Antiviral Res. 10:153-166.
18. Loomis, M. R., T. O'Neill, M. Bush, and R. J. Montali. 1981. Fatal herpes-virus infection in patas monkeys and a black and white colobus monkey. J. Am. Vet. Med. Assoc. 179:1236-1239.
19. Mansuri, M. M., I. Ghazzouli, M. S. Chen, H. G. Howell, P. R. Brodfuehrer, D. A. Benigni, and J. C. Martin. 1987. 1-(2-Deoxy-2-fluoro- beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent. J. Med. Chem. 30:867-871.
20. Nanda, M., V. T. Curtin, J. K. Hilliard, N. D. Bernstein, and R. D. Dix. 1990. Ocular histopathologic findings in a case of human herpes B virus infection. Arch. Ophthalmol. 108:713-716.
21. Ohsawa, K., D. H. Black, R. Torii, H. Sato, and R. Eberle. 2002. Detection of a unique genotype of monkey B virus (Cercopithecine herpesvirus 1) indigenous to native Japanese macaques (Macaca fuscata). Comp. Med. 52:555-559.
22. Palmer, A. E. 1987. B virus, Herpesvirus simiae: historical perspective. J. Med. Primatol. 16:99-130.
23. Poffenberger, K. L., and B. Roizman. 1985. A noninverting genome of a viable herpes simplex virus 1: presence of head-to-tail linkages in packaged genomes and requirements for circularization after infection. J. Virol. 53: 587-595.
24. Reardon, J. E. 1989. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues. J. Biol. Chem. 264:19039-19044.
25. Smith, A. L., D. H. Black, and R. Eberle. 1998. Molecular evidence for distinct genotypes of monkey B virus (herpesvirus simiae) which are related to the macaque host species. J. Virol. 72:9224-9232.
26. Soike, K. F., T. C. Chou, J. J. Fox, K. A. Watanabe, and C. A. Gloff. 1990. Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-beta. Antiviral Res. 13:165-174.
27. Tognon, M., E. M. Cattozzo, S. Bianchi, and M. G. Romanelli. G. 1996. Enhancement of HSV-DNA infectivity, in Vero and RS cells, by a modified calcium-phosphate transfection technique. Virus Genes 12:193-197.
28. Trousdale, M. D., J. L. Law, F. A. Yarber, K. A. Watanabe, and J. J. Fox. 1992. Evaluation of 1-(2′-deoxy-2′-fluoro-beta-D- arabinofuranosyl)-5-ethyluracil in a rabbit model of herpetic keratitis. Antiviral Res. 17:157-167.
29. U.S. Department of Health and Human Services Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. 2007. Biosafety in microbiological and biomedical laboratories, 5th ed. Government Printing Office, Washington, DC. http://www.cdc.gov/OD /OHS/biosfty/bmbl5/BMBL-5th-Edition.pdf.
30. Van Etta, L., J. Brown, A. Mastri, and T. Wilson. 1981. Fatal vidarabine toxicity in a patient with normal renal function. JAMA 246:1703-1705.
31. Vizoso, A. D. 1975. Recovery of herpes simiae (B virus) from both primary and latent infections in rhesus monkeys. Br. J. Exp. Pathol. 56:485-488.
32. Wall, L. V., H. T. Zwartouw, and D. C. Kelly. 1989. Discrimination between twenty isolates of herpesvirus simiae (B virus) by restriction enzyme analysis of the viral genome. Virus Res. 12:283-296.
33. Watanabe, K. A., U. Reichman, K. Hirota, C. Lopez, and J. J. Fox. 1979. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2′-fluoro-2′-deoxyarabinofuranosylpyrimidine nucleosides. J. Med. Chem. 22:21-24.
34. Weigler, B. J. 1992. Biology of B virus in macaque and human hosts: a review. Clin. Infect. Dis. 14:555-567.
35. Whitley, R. J., and C. A. Alford. 1981. Antiviral agents: clinical status report. Hosp. Pract. (Off. Ed.) 16:109-121.
36. Wild, K., T. Bohner, G. Folkers, and G. E. Schulz. 1997. The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Sci. 6:2097-2106.
37. Wilson, R. B., M. A. Holscher, T. Chang, and J. R. Hodges. 1990. Fatal Herpesvirus simiae (B virus) infection in a patas monkey (Erythrocebus patas). J. Vet. Diagn. Invest. 2:242-244.
38. Zwartouw, H. T., and E. A. Boulter. 1984. Excretion of B virus in monkeys and evidence of genital infection. Lab. Anim. 18:65-70.
39. Zwartouw, H. T., C. R. Humphreys, and P. Collins. 1989. Oral chemotherapy of fatal B virus (herpesvirus simiae) infection. Antiviral Res. 11:275-283.